CAL
MXCT icon

Capital Advisors Ltd’s MaxCyte MXCT Stock Holding History

Capital Advisors Ltd’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-44
Closed – – 1426
2022
Q4 		$0 Buy
+44
New +$270 ﹤0.01% 1485

Other funds holding MXCT

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $159M AUM 139.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

Capital Advisors Ltd's MXCT Position: Q1 2023 in Review

Capital Advisors Ltd sold out of MaxCyte (MXCT) in Q1 2023, closing a stake of 44 shares.

Capital Advisors Ltd first reported a position in MXCT in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 114 funds tracked by Wall St. Rank hold MXCT as of Q1 2023.

  • Capital Advisors Ltd reported no remaining MaxCyte position as of Q1 2023 after selling out during the quarter.
  • Capital Advisors Ltd sold 44 MaxCyte shares in Q1 2023.
  • Capital Advisors Ltd first reported a position in MaxCyte in Q4 2022 and held it in 1 quarter.
  • Capital Advisors Ltd's MaxCyte position peaked at $0 in Q4 2022.
  • 114 funds tracked by Wall St. Rank held MaxCyte as of Q1 2023.

Based on Capital Advisors Ltd's 13F filing for Q1 2023, filed 3 May 2023.